Join to View Full Profile
3200 Burnet AveCincinnati, OH 45229
Phone+1 513-475-8500
Fax+1 513-584-4281
Dr. Lemmon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Assistant professor of medicine at the University of Cincinnati College of Medicine specializing in lung cancer and head & neck cancers at the Barrett Cancer Center. Former heme/onc chief fellow at Cleveland Clinic and former patient safety fellow at University of Florida COM-Jacksonville.
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2019 - 2022
University of Florida College of Medicine - JacksonvillePost-Doctoral Fellowship, 2018 - 2019
Medical College of GeorgiaResidency, Internal Medicine, 2015 - 2018
St. George's University School of MedicineClass of 2015, MD, Cum Laude
The Ohio State UniversityBS, Microbiology, 2003 - 2008
Certifications & Licensure
GA State Medical License 2018 - 2027
OH State Medical License 2019 - 2026
FL State Medical License 2018 - 2022
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 12 citationsModeling Costs and Life-Years Gained by Population-Wide Next-Generation Sequencing or Single-Gene Testing in Nonsquamous Non-Small-Cell Lung Cancer in the United States.Christopher A Lemmon, Jie Zhou, Brian Hobbs, Nathan A Pennell
JCO Precision Oncology. 2023-01-01 - 6 citationsA Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC.Christopher A Lemmon, Gregory M M Videtic, Sudish Murthy, Kevin L Stephans, Marc Shapiro
JTO Clinical and Research Reports. 2022-07-01 - 9 citationsModeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer.Christopher A Lemmon, Emily C Zabor, Nathan A Pennell
The Oncologist. 2022-05-06
Journal Articles
- Angiogenesis and Anti-tumor Immunity in the Tumor Microenvironment: Opportunities for Synergism in InterventionLemmon C., Sadek I., Hao Z., JNSCI, 10/2017
Abstracts/Posters
- A phase I safety and feasibility study of neoadjuvant chemoradiation plus pembrolizumab followed by consolidation pembrolizumab in resectable stage IIIA non-small cell...Christopher Lemmon, Gregory Videtic, Sudish Murthy, Kevin Stephans, Marc Shapiro, Usman Ahmad, Daniel Raymond, Vamsidhar Velcheti, Alejandro Bribriesco, and Nathan A. ..., J Clin Oncol 38: 2020 (suppl; abstr 9009), ASCO Annual Meeting Virtual Scientific Program, May 27-31, 2020., 5/27/2020
- Finding the root causes: Development of a patient safety simulation course for graduate medical educationLemmon, C., Anwar, A., Godwin, S.A., Burden, S., Chrobot, K., Harrison, A., Hendrickson, S., Institute for Healthcare Improvement Patient Safety Congress, Houston, TX, 5/2019
- Improving the safety of cesarean sections through development of a team dynamic and communication simulation courseAnwar, A., Lemmon, C., Godwin, S.A., Diachun, C., Institute for Healthcare Improvement Patient Safety Congress, Houston, TX, 5/2019
- Join now to see all
Press Mentions
Calculating the Cost of Widespread Genetic Sequencing in NSCLCJanuary 23rd, 2024
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
